RnRMarketResearch.com adds “Hypogonadotropic Hypogonadism – Pipeline Review, H1 2015” to its store.
The report ‘Hypogonadotropic Hypogonadism – Pipeline Review, H1 2015′, provides an overview of the Hypogonadotropic Hypogonadism’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hypogonadotropic Hypogonadism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypogonadotropic Hypogonadism and special features on late-stage and discontinued projects.
Complete report is available at http://www.rnrmarketresearch.com/hypogonadotropic-hypogonadism-pipeline-review-h1-2015-market-report.html .
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Order a copy of this report at (Prices start at US $ 2000 for a single user PDF) http://www.rnrmarketresearch.com/contacts/purchase?rname=310205 .
Companies discussed in this report include AlphaMab Co., Ltd, Forendo Pharma Oy, Merck & Co., Inc., Novartis AG, Repros Therapeutics Inc.
Drugs profiled discussed in this report include BGS-649, corifollitropin alfa, enclomiphene, fispemifene, follitropin alfa, Kisspeptin-10, testosterone undecanoate.
Featured News & Press Releases:
· Oct 27, 2014: Repros to Webcast Investor and Analyst Day on October 31st
· Oct 21, 2014: Results From Long-Term Study of Androxal Exhibit Positive Safety Profile
· Sep 26, 2014: FDA Schedules Type B Pre-NDA Meeting With Repros
· Sep 25, 2014: Androxal Second Pivotal Study Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints Versus Marketed Topical Gel in the Treatment of Secondary Hypogonadism
· Jul 16, 2014: FDA Confirms Sperm and Testosterone Endpoints as Key Parameters for Assessment of Androxal Versus Approved Topical Gel and Placebo
· May 13, 2014: Repros Fully Enrolls Second Previously Announced Head to Head Study of Androxal(R) Versus the Leading Topical Testosterone Gel
· Apr 30, 2014: FDA Recommends Sperm Endpoints as Key Parameters for Assessment of Androxal Versus Approved Topical Gel
· Apr 14, 2014: Repros Fully Enrolls First of Two Previously Announced Head to Head Studies of Androxal Versus the Leading Topical Testosterone Gel
· Jan 08, 2014: Repros Initiates Two Head to Head Studies of Androxal Versus the Leading Topical Testosterone Gel
· Nov 25, 2013: FDA Schedules Face to Face Meeting With Repros to Discuss Androxal Efficacy
List of Tables